Oral Oncolytic Medications – Guide to Patient Education Materials

  1. The patient education documents summarize the key counseling points for each of the oral oncolytic medications, including:
  2. A short summary about the medication
  3. Information regarding how to take the medication
  4. Important precautions
  5. Food/drug and drug/drug interactions
  6. Safe handling, storage, and disposal
  7. The most common side effects and self-care management
  1. The side effect portion of the document is the second part of the document:
  2. This section of the document can be printed for patients at each clinic visit as a reminder of the most common side effects and how to manage them.
  3. Side effects and management of side effects are divided by National Cancer Institute Common Toxicity Criteria grading (in patient language), so that patients can assess and safely manage their own side effects and know when to call the clinic or seek emergency help when necessary
  1. The final portion of the document is a form for patients to track and record information that clinicians would find useful at each clinic visit, including:
  2. Number of missed doses
  3. Problems receiving the medication (cost or access issues)
  4. Symptoms and interventions patients have tried
  5. Other concerns or questions
  6. There are 6 copies of this form included at the end of the patient education packet, so that patients can tear a form off and record this information for each clinic visit.
  1. These patient education documents must be reviewed by a physician at your practice before distribution to patients and on a periodic basis as defined by your practice.

Please contact with any questions.

References:

  1. Xtandi [package insert]. Astellas Pharma US, Inc., Northbrook, IL; August 2012. Accessed July 19, 2013.
  2. Zytiga [package insert]. Janssen Biotech, Inc., Horsham, PA; December 2012. Accessed August 18, 2013.
  3. Xeloda [package insert]. Genentech, Inc., South San Francisco, CA; February 2011. Accessed August 20, 2013.
  4. Revlimid [package insert]. Celgene Corporation. Summit, NJ; June 2013. Accessed August 20, 2013.
  5. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. U.S. Department of Health and Human Services, National Institutes of Health - National Cancer Institute. Updated June 14, 2010. Accessed July 19, 2013.
  6. Goodin S, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011 Jan;7(1):7-12.
  7. Mustian KM, et al. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist. 2007;12 Suppl 1:52-67. Review.
  8. Chobanian AV, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72.
  9. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006 Sep;12(3):131-41. Review.
  10. Basch EM, et al. Electronic toxicitymonitoring and patient-reported outcomes. Cancer J. 2011 Jul-Aug;17(4):231-4.

Copyright 2017 Michigan Oncology Quality Consortium, All rights reserved. V.12-14